Aliases & Classifications for Mood Disorder

Aliases & Descriptions for Mood Disorder:

Name: Mood Disorder 12 14
Mood Disorders 52 41 42 69
Episodic Mood Disorder 12 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3324
MeSH 42 D019964
NCIt 47 C92200
UMLS 69 C0525045

Summaries for Mood Disorder

MedlinePlus : 41 most people feel sad or irritable from time to time. they may say they're in a bad mood. a mood disorder is different. it affects a person's everyday emotional state. nearly one in ten people aged 18 and older have mood disorders. these include depression and bipolar disorder (also called manic depression). mood disorders can increase a person's risk for heart disease, diabetes, and other diseases. treatments include medication, psychotherapy, or a combination of both. with treatment, most people with mood disorders can lead productive lives.

MalaCards based summary : Mood Disorder, also known as mood disorders, is related to schizophrenia and personality disorder, and has symptoms including alexithymia and psychiatric symptom. An important gene associated with Mood Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Valproic Acid and Amitriptyline have been mentioned in the context of this disorder. Affiliated tissues include heart, cortex and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves an excessive, irrational dread of everyday situations.

Wikipedia : 71 Mood disorder is a group of diagnoses in the Diagnostic and Statistical Manual of Mental Disorders (DSM)... more...

Related Diseases for Mood Disorder

Diseases related to Mood Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
id Related Disease Score Top Affiliating Genes
1 schizophrenia 30.9 BDNF CACNA1C COMT DRD2 DRD4 HTR1A
2 personality disorder 29.9 BDNF COMT CRH DRD2 DRD4 HTR1A
3 dissociative disorder 29.8 DRD4 MAOA MAOB
4 autism spectrum disorder 29.6 BDNF COMT DRD4 POMC SLC6A4
5 bipolar disorder 11.1
6 delusional disorder 11.1
7 panic disorder 10.9
8 organic mood syndrome 10.9
9 polycystic ovary syndrome 10.9
10 pituitary adenoma, acth-secreting 10.7
11 dysthymic disorder 10.7
12 47,xyy syndrome 10.7
13 schizophrenia 17 10.6
14 schizophrenia susceptibility 18 10.6
15 schizophrenia 4 10.6
16 schizophrenia 15 10.6
17 impulse control disorder 10.6
18 atypical depressive disorder 10.6
19 endogenous depression 10.6
20 cyclothymic disorder 10.6
21 nephronophthisis 13 10.4 COMT HTR2A SLC6A4
22 dry eye syndrome 10.4 HTR1A HTR2A SLC6A4
23 neurogenic bladder 10.4 HTR2A MAOA SLC6A4
24 ornithosis 10.4 DRD2 MAOA SLC6A4
25 adult brainstem astrocytoma 10.4 HTR1A MAOA SLC6A4
26 splenic abscess 10.4 DRD2 HTR2A SLC6A4
27 teratoma with malignant transformation 10.4 BDNF DRD2 HTR2A
28 kidney pelvis papillary carcinoma 10.4 HTR1A MAOA SLC6A4
29 euthyroid sick syndrome 10.3 DRD2 HTR2A SLC6A4
30 tinea pedis 10.3 HTR1A MAOA SLC6A4
31 deafness, autosomal recessive 20 10.3 CRH SLC6A4 TPH1
32 sphenoorbital meningioma 10.3 DRD2 DRD4 TH
33 urea cycle disorder 10.3 BDNF COMT DRD2
34 allergic hypersensitivity disease 10.3 DRD2 HTR1A HTR2A
35 vascular cancer 10.3 DRD2 HTR1A HTR2A
36 apperceptive agnosia 10.3 COMT DRD2 HTR1A SLC6A4
37 waardenburg's syndrome 10.3 DRD2 HTR1A HTR2A SLC6A4
38 alopecia 10.3 BDNF DRD2 DRD4 SLC6A4
39 siberian tick typhus 10.3 BDNF CREB1 HTR1A
40 c8 deficiency, type ii 10.3 COMT CREB1 DRD2 DRD4
41 anodontia 10.3 HTR1A HTR1B SLC6A4
42 conjunctival pigmentation 10.3 CRH MAOA MAOB SLC6A4
43 intrahepatic gall duct cancer 10.3 BDNF COMT HTR2A MAOA SLC6A4
44 tuberculous peritonitis 10.3 CRH SLC6A4 TPH1
45 primary angle-closure glaucoma 10.3 BDNF COMT HTR1A HTR2A SLC6A4
46 breast reconstruction 10.3 BDNF COMT DRD2
47 lethal congenital contracture syndrome 1 10.3 COMT MAOA MAOB TH
48 colorectal adenocarcinoma 10.3 COMT DRD2 DRD4 MAOA SLC6A4
49 nonparalytic poliomyelitis 10.3 CRH NR3C1 POMC
50 pythiosis 10.3 MAOA MAOB TH

Comorbidity relations with Mood Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety Disorder
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Hypothyroidism Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Schizophreniform Disorder

Graphical network of the top 20 diseases related to Mood Disorder:



Diseases related to Mood Disorder

Symptoms & Phenotypes for Mood Disorder

UMLS symptoms related to Mood Disorder:


alexithymia, psychiatric symptom

MGI Mouse Phenotypes related to Mood Disorder:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.51 CRH DRD2 DRD4 HTR1A HTR1B HTR2A
2 homeostasis/metabolism MP:0005376 10.39 BDNF CACNA1C COMT CREB1 CRH DRD2
3 cardiovascular system MP:0005385 10.34 CACNA1C HTR1B MAOA NR3C1 POMC SLC18A2
4 endocrine/exocrine gland MP:0005379 10.26 BDNF CACNA1C COMT CREB1 CRH DRD2
5 nervous system MP:0003631 10.25 POMC SLC18A2 SLC6A4 TACR1 TH BDNF
6 growth/size/body region MP:0005378 10.23 BDNF CREB1 CRH DRD2 HTR1B NPY
7 integument MP:0010771 10.1 TH TPH1 BDNF CACNA1C CRH DRD2
8 muscle MP:0005369 10.02 CACNA1C CREB1 DRD2 HTR1B HTR2A NR3C1
9 adipose tissue MP:0005375 10 CRH DRD2 NPY NR3C1 POMC TPH1
10 no phenotypic analysis MP:0003012 9.86 BDNF CRH DRD2 HTR1A HTR1B NR3C1
11 renal/urinary system MP:0005367 9.7 COMT CRH DRD2 MAOB NPY NR3C1
12 respiratory system MP:0005388 9.61 BDNF COMT CREB1 CRH DRD2 NR3C1
13 skeleton MP:0005390 9.28 CRH DRD2 HTR1B HTR2A NPY NR3C1

Drugs & Therapeutics for Mood Disorder

Drugs for Mood Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 875)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
2
Amitriptyline Approved Phase 4,Phase 3,Phase 2 50-48-6 2160
3
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59729-33-8 2771
4
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
5
Nortriptyline Approved Phase 4,Phase 2,Phase 1 72-69-5 4543
6
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
7
Perphenazine Approved Phase 4,Phase 3,Phase 2 58-39-9 4748
8
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 79617-96-2 68617
9
Trimipramine Approved Phase 4 739-71-9 5584 4055
10
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1 34841-39-9, 34911-55-2 444
11
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
12
Acetylcholine Approved Phase 4,Phase 2,Phase 1 51-84-3 187
13
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Early Phase 1 58-18-4 6010
14
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 58-22-0 6013
15
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54910-89-3 3386
16
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 6740-88-1 3821
17
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2 28523-86-6 5206
18
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 75614-87-8, 51-45-6 774
19
Mianserin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 24219-97-4 4184
20
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85650-52-8, 61337-67-5 4205
21
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-23-7 5754 657311
22
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
23
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
24
Fluvoxamine Approved, Investigational Phase 4,Phase 3 54739-18-3 3404 5324346
25
Trazodone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 19794-93-5 5533
26
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
27
Tranylcypromine Approved Phase 4,Phase 1,Phase 2,Early Phase 1 155-09-9 441233
28
Ropinirole Approved, Investigational Phase 4,Phase 3 91374-20-8, 91374-21-9 5095 497540
29
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
30
Rasagiline Approved Phase 4 136236-51-6 3052776
31
Copper Approved Phase 4 15158-11-9, 7440-50-8 27099
32
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757 53477783
33
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1 57-63-6 5991
34
Norethindrone Approved Phase 4,Phase 2 68-22-4 6230
35
Reboxetine Approved, Investigational Phase 4,Phase 2,Phase 1 98769-81-4, 71620-89-8 123628 65856
36
Eszopiclone Approved Phase 4,Phase 3,Phase 2,Phase 1 138729-47-2 969472
37
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 298-46-4 2554
38
Coal tar Approved Phase 4,Phase 2 8007-45-2
39
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 132539-06-1 4585
40
Oxcarbazepine Approved Phase 4,Phase 2,Phase 3 28721-07-5 34312
41
Ziprasidone Approved Phase 4,Phase 2,Phase 3 146939-27-7 60854
42
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 113-45-1 4158
43
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 106266-06-2 5073
44
Acamprosate Approved, Investigational Phase 4,Phase 1,Phase 2 77337-76-9 71158
45
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2 27203-92-5 33741
46
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
47
Topiramate Approved Phase 4,Phase 3,Phase 2 97240-79-4 5284627
48
Clozapine Approved Phase 4,Phase 3,Phase 2 5786-21-0 2818
49
Etomidate Approved Phase 4 33125-97-2 36339 667484
50
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 2078-54-8 4943

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD) Unknown status NCT01272531 Phase 4
2 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4
3 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4
4 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
5 Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4
6 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4
7 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
8 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4
9 Duloxetine for Major Depression in Peri-/Postmenopausal Women Unknown status NCT00889369 Phase 4
10 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4
11 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4
12 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4
13 Medications for the Treatment of Dysthymic Disorder and Double Depression Unknown status NCT00234312 Phase 4
14 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4
15 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4
16 Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy Unknown status NCT02267980 Phase 4
17 The Effect of Duloxetine on Interoceptive Awareness Unknown status NCT00337012 Phase 4
18 Treatment of Mild and Subthreshold Depressive Disorders Unknown status NCT00226642 Phase 4
19 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4
20 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4
21 Morbidity and Mortality Among Dialysis Patients After Treatment for Depression Unknown status NCT00442429 Phase 4
22 Cymbalta for Depression as a Complication of Bereavement Unknown status NCT00658931 Phase 4
23 Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4
24 Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4
25 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4
26 Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression Unknown status NCT01390662 Phase 4
27 Lithium and Standard Therapy in Resistant Depression Unknown status NCT00927550 Phase 4
28 Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression Unknown status NCT00106197 Phase 4
29 Effect of Antidepressants on White Matter Structure Unknown status NCT01492621 Phase 4
30 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4
31 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4
32 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4
33 Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4
34 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4
35 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4
36 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4
37 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4
38 Tranylcypromine Treatment of Bipolar Depression Unknown status NCT01430455 Phase 4
39 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4
40 Desvenlafaxine vs. Placebo Treatment of Chronic Depression Unknown status NCT01537068 Phase 4
41 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
42 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4
43 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4
44 Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder Unknown status NCT01699490 Phase 4
45 Emotion, Mood and Executive Function in Parkinson`s Disease (PD) Unknown status NCT01385735 Phase 4
46 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4
47 A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care Unknown status NCT00939250 Phase 4
48 Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales Unknown status NCT02210702 Phase 4
49 Diabetes and Depression in Hispanics and African Americans: Treatment of Depression With Sertraline and Its Effect on A1c and Quality of Life Unknown status NCT00624013 Phase 4
50 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4

Search NIH Clinical Center for Mood Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: mood disorders

Genetic Tests for Mood Disorder

Anatomical Context for Mood Disorder

MalaCards organs/tissues related to Mood Disorder:

39
Heart, Cortex, Brain, Thyroid, Pituitary, Testes, Prefrontal Cortex

Publications for Mood Disorder

Articles related to Mood Disorder:

(show top 50) (show all 778)
id Title Authors Year
1
Narcissistic Personality Disorder and suicidal behavior in mood disorders. ( 27816770 )
2017
2
Could EPO studies improve mood disorder treatment strategies? ( 27967254 )
2017
3
A comparative meta-analysis of TEMPS scores across mood disorder patients, their first-degree relatives, healthy controls, and other psychiatric disorders. ( 26897455 )
2016
4
Effect of lithium on thyroid function in adolescents with mood disorder. ( 27931904 )
2016
5
Changes in cortical N-methyl-D-aspartate receptors and post-synaptic density protein 95 in schizophrenia, mood disorders and suicide. ( 26013316 )
2016
6
Integrating Early Intervention for Borderline Personality Disorder and Mood Disorders. ( 27144298 )
2016
7
Melatonin and pro-hypnotic effectiveness of the antidepressant Trazodone: A preliminary evaluation in insomniac mood-disorder patients. ( 27374436 )
2016
8
Ultrasonographically Measured Change in Thyroid Status in Lithium Treated Adult Patients with Mood Disorder. ( 27114623 )
2016
9
Targeting Treatments to Improve Cognitive Function in Mood Disorder: Suggestions From Trials Using Erythropoietin. ( 27835716 )
2016
10
Circadian Gene Circuitry Predicts Hyperactive Behavior in a Mood Disorder Mouse Model. ( 27028761 )
2016
11
Mood disorders in healthy elderly with obstructive sleep apnea: a gender effect. ( 27198948 )
2016
12
Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression ("RAD") project. ( 26980207 )
2016
13
Histories of abuse predict stronger within-person covariation of ovarian steroids and mood symptoms in women with menstrually related mood disorder. ( 26896670 )
2016
14
Functioning Among Youth with Comorbid Mood Disorder and Chronic Physical Illness in Public Sector Care. ( 27680986 )
2016
15
The Effect of Family-Centered Psycho-Education on Mental Health and Quality of Life of Families of Adolescents with Bipolar Mood Disorder: A Randomized Controlled Clinical Trial. ( 27382589 )
2016
16
Exploring the Use of Information and Communication Technology by People With Mood Disorder: A Systematic Review and Metasynthesis. ( 27370327 )
2016
17
Branched-Chain Amino Acids as New Biomarkers of Major Depression - A Novel Neurobiology of Mood Disorder. ( 27490818 )
2016
18
Treatment of Postpartum Mood Disorder in Iran. ( 27903108 )
2016
19
A Magnetic Resonance Spectroscopy study of lovastatin for treating Bipolar Mood disorder, A-4 week Randomized Double Blind, Placebo- Controlled Clinical Trial. ( 27804862 )
2016
20
Presence or absence of cognitive complaints in Parkinson's disease: mood disorder or anosognosia? ( 27332067 )
2016
21
Anxiety or agitation in mood disorder with mixed features: A review with a focus on validity as a dimensional criterion. ( 27490837 )
2016
22
Illness history: Not associated with remission during treatment of major depression in 515 mood disorder patients. ( 26655121 )
2016
23
Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987-2010. ( 26748100 )
2016
24
Effect of obesity on cognition in adults with and without a mood disorder: study design and methods. ( 26928024 )
2016
25
Predictors for Reconstruction and Mood Disorder Associated With Reconstruction in Patients With Breast Cancer and Mastectomy: A Retrospective Cohort Study. ( 26817890 )
2016
26
Low birth weight and features of neuroticism and mood disorder in 83a88545 participants of the UK Biobank cohort. ( 27703752 )
2016
27
Clinical and genetic factors associated with suicide in mood disorder patients. ( 26626456 )
2016
28
Sini powder () decoction alleviates mood disorder of insomnia by regulating cation-chloride cotransporters in hippocampus. ( 26597287 )
2015
29
Serotonin gene polymorphisms and lifetime mood disorders in predicting interferon-induced depression in chronic hepatitis C. ( 26001668 )
2015
30
Treatment of mood disorders in multiple sclerosis. ( 25398464 )
2015
31
Childhood dissociation as a precursor of mood disorder: A 5 years follow-up case study. ( 25657477 )
2015
32
Association of paraoxonase (PON)1 activity, glutathione S-transferase GST T1/M1 and STin.2 polymorphisms with comorbidity of tobacco use disorder and mood disorders. ( 25445355 )
2015
33
Possible exogenous growth hormone induced mood disorder with mixed features in a child. ( 25885016 )
2015
34
Depression and Mood Disorder Among African American and White Women-Reply. ( 26561331 )
2015
35
Increased Anxiety, Akathisia, and Suicidal Thoughts in Patients with Mood Disorder on Aripiprazole and Lamotrigine. ( 26509095 )
2015
36
The Effect of Bipolar Mood Disorder on Sadegh Hedayat's Letters. ( 25708966 )
2015
37
Early exposure to parental bipolar disorder and risk of mood disorder: the Flourisha88Canadian prospective offspring cohort study. ( 26486425 )
2015
38
A randomised control trial of an Internet-based cognitive behaviour treatment for mood disorder in adults with chronic spinal cord injury. ( 26690861 )
2015
39
Organic Mood Disorder Following Left Anterior Temporal Lobectomy with Amygdalohippocampectomy. ( 26702178 )
2015
40
Relationship between affective temperaments and aggression in euthymic patients with bipolar mood disorder and major depressive disorder. ( 25474481 )
2015
41
MDMA for the treatment of mood disorder: all talk no substance? ( 26199721 )
2015
42
Psychological Characteristics of Problem Gamblers With and Without Mood Disorder. ( 26454559 )
2015
43
A tale of two diatheses: Temperament, BIS, and BAS as risk factors for mood disorder. ( 25913803 )
2015
44
Time zone travel and circadian mechanisms in mood disorder: Some blue-sky thinking. ( 26320235 )
2015
45
Demonstrating the Role of Anticholinergic Activity in a Mood Disorder. ( 26138496 )
2015
46
Mood disturbance in adolescents screened by the Mood Disorder Questionnaire predicts poorer social adjustment. ( 26003581 )
2015
47
The influence of early life sexual abuse on oxytocin concentrations and premenstrual symptomatology in women with a menstrually related mood disorder. ( 25892085 )
2015
48
No association between wolframin gene H611R polymorphism and mood disorders: evidence from 2,570 subjects. ( 25074416 )
2015
49
Does Mood Disorder Questionnaire identify sub-threshold bipolarity? Evidence studying worsening of quality of life. ( 26021966 )
2015
50
Hypersomnia in Mood Disorders: a Rapidly Changing Landscape. ( 26258003 )
2015

Variations for Mood Disorder

Expression for Mood Disorder

Search GEO for disease gene expression data for Mood Disorder.

Pathways for Mood Disorder

Pathways related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 28)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.51 CRH DRD2 DRD4 HTR1A HTR1B HTR2A
2
Show member pathways
12.64 CACNA1C COMT CREB1 DRD2 DRD4 MAOA
3 12.53 COMT CREB1 HTR1A NPY POMC TH
4 12.26 CACNA1C CREB1 DRD2 DRD4
6
Show member pathways
12.22 BDNF CACNA1C CREB1 DRD2 HTR1A HTR1B
7
Show member pathways
12.12 CACNA1C CREB1 DRD2 DRD4
8
Show member pathways
11.95 DRD2 DRD4 HTR1A HTR1B HTR2A
9
Show member pathways
11.93 BDNF CACNA1C CREB1 DRD2 MAOA MAOB
10
Show member pathways
11.87 DRD2 DRD4 SLC18A2 TH
11 11.78 CREB1 CRH POMC
12 11.76 MAOA TH TPH1
13 11.7 CREB1 NR3C1 POMC
14
Show member pathways
11.7 COMT MAOA MAOB TH
15 11.68 BDNF SLC18A2 TH
16 11.66 CACNA1C HTR1A HTR1B HTR2A MAOA MAOB
17 11.53 BDNF CREB1 HTR1A HTR2A MAOA NR3C1
18
Show member pathways
11.39 MAOA SLC6A4 TH
19
Show member pathways
11.17 COMT MAOA SLC6A4
20 11.15 HTR1A HTR1B HTR2A MAOA SLC18A2 SLC6A4
21
Show member pathways
11.1 COMT MAOA TH TPH1
22 11.09 CACNA1C NPY SLC18A2
23 10.88 COMT MAOA MAOB TH
24
Show member pathways
10.83 COMT MAOA MAOB
25 10.78 BDNF CREB1
26
Show member pathways
10.74 MAOA MAOB
27 10.7 CACNA1C TH
28 10.44 CRH POMC

GO Terms for Mood Disorder

Cellular components related to Mood Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.56 DRD2 DRD4 HTR1A HTR1B HTR2A SLC18A2
2 dendrite GO:0030425 9.55 COMT DRD2 HTR2A TACR1 TH
3 axon GO:0030424 9.02 COMT CREB1 DRD2 HTR2A TH

Biological processes related to Mood Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.97 CREB1 DRD2 SLC6A4 TH
2 response to estradiol GO:0032355 9.9 SLC6A4 TACR1 TH
3 response to toxic substance GO:0009636 9.9 DRD2 MAOB SLC18A2 SLC6A4
4 locomotory behavior GO:0007626 9.89 DRD2 SLC18A2 TH
5 circadian rhythm GO:0007623 9.89 CREB1 SLC6A4 TPH1
6 regulation of blood pressure GO:0008217 9.86 NPY POMC TACR1
7 social behavior GO:0035176 9.84 DRD4 SLC6A4 TH
8 positive regulation of fat cell differentiation GO:0045600 9.83 CREB1 HTR2A TPH1
9 feeding behavior GO:0007631 9.83 DRD2 HTR1B NPY
10 response to cocaine GO:0042220 9.83 CRH DRD2 HTR1B
11 memory GO:0007613 9.81 CREB1 HTR2A SLC6A4 TH
12 chemical synaptic transmission GO:0007268 9.8 CRH HTR1B HTR2A NPY SLC18A2 TACR1
13 associative learning GO:0008306 9.79 CRH DRD2 TACR1
14 response to immobilization stress GO:0035902 9.76 CRH TH TPH1
15 regulation of dopamine secretion GO:0014059 9.75 DRD2 HTR1B HTR2A
16 behavioral response to cocaine GO:0048148 9.74 DRD2 DRD4 HTR2A
17 negative regulation of cAMP biosynthetic process GO:0030818 9.73 DRD4 HTR1B
18 response to pain GO:0048265 9.73 COMT CRH TACR1
19 positive regulation of kinase activity GO:0033674 9.72 DRD4 HTR2A
20 behavioral response to ethanol GO:0048149 9.72 DRD2 DRD4
21 neurotransmitter biosynthetic process GO:0042136 9.72 SLC6A4 TH
22 positive regulation of long-term synaptic potentiation GO:1900273 9.72 CREB1 DRD2
23 vasoconstriction GO:0042310 9.72 HTR1A HTR1B SLC6A4
24 positive regulation of renal sodium excretion GO:0035815 9.71 DRD2 TACR1
25 negative regulation of protein secretion GO:0050709 9.71 DRD2 DRD4
26 negative regulation of voltage-gated calcium channel activity GO:1901386 9.71 DRD2 DRD4
27 bone remodeling GO:0046849 9.71 HTR1B TPH1
28 synaptic transmission, dopaminergic GO:0001963 9.71 CRH DRD2 TH
29 G-protein coupled receptor internalization GO:0002031 9.7 DRD2 HTR1B
30 positive regulation of hormone secretion GO:0046887 9.7 CREB1 TACR1
31 cellular response to alkaloid GO:0071312 9.7 HTR1B TH
32 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.7 DRD2 DRD4
33 response to corticosterone GO:0051412 9.7 CRH MAOB TH
34 catecholamine metabolic process GO:0006584 9.69 COMT MAOA
35 regulation of appetite GO:0032098 9.69 NPY POMC
36 regulation of dopamine metabolic process GO:0042053 9.69 DRD4 HTR1A
37 monoamine transport GO:0015844 9.68 SLC18A2 SLC6A4
38 aromatic amino acid family metabolic process GO:0009072 9.68 TH TPH1
39 serotonin receptor signaling pathway GO:0007210 9.68 HTR1A HTR2A
40 sperm ejaculation GO:0042713 9.67 SLC6A4 TACR1
41 regulation of hormone secretion GO:0046883 9.67 HTR1A HTR2A
42 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.67 DRD2 HTR1B HTR2A
43 response to nicotine GO:0035094 9.67 CREB1 DRD2 TACR1 TH
44 negative regulation of serotonin secretion GO:0014063 9.65 HTR1B MAOB
45 dopamine metabolic process GO:0042417 9.65 COMT DRD2 DRD4
46 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.64 HTR1A HTR1B
47 response to ether GO:0045472 9.64 CRH TH
48 aminergic neurotransmitter loading into synaptic vesicle GO:0015842 9.63 SLC18A2 TH
49 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.63 DRD2 DRD4
50 neurotransmitter catabolic process GO:0042135 9.63 COMT MAOA MAOB

Molecular functions related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.98 DRD2 DRD4 HTR1A HTR1B HTR2A NPY
2 signal transducer activity GO:0004871 9.73 DRD2 DRD4 HTR1A HTR1B HTR2A TACR1
3 G-protein coupled serotonin receptor activity GO:0004993 9.54